|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Laquinimod>> Market Analysis Reports |
Market Analysis Reports of Laquinimod |
|
Active Biotech AB Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... . Its projects in clinical development include Laquinimod, an oral immunomodulatory agent that is in Phase ... Multiple Sclerosis Therapeutics Market Analysis By Drug Class (Immunomodulators, Immunosuppressant, Copaxone, Avonex, Gilenya, Tysabri, Betaseron, Tecfidera, Rebif, Ampyra, Aubagio, Extavia, Plegridy, Alemtuzumab, Glatopa, Siponimod, Ocrelizumab, Laquinimod, Zinbryta), By Mode of Administration (Oral, Injectable, Intravenous) And Segment Forecasts To 2024 The global multiple sclerosis therapeutics market is expected to reach USD 24.8 billion by 2024 according to a new report by Grand View Research, Inc. The presence of high unmet clinical needs in developing regions is one of the highest impact rendering ... Multiple Sclerosis - KOL Insight and Consensus Outlook Modules ... Lemtrada (alemtuzumab; Genzyme/Sanofi) forecast Laquinimod (Teva/Active Biotech) forecast Daclizumab ... Multiple Sclerosis: KOL Insight ... , DAC-HYP; Biogen/AbbVie) Nerventra (laquinimod; Active Biotech/Teva) Ozanimod (RPC ... Global Primary Progressive Multiple Sclerosis Treatment Market Insight 2020, Forecast to 2025 ... : ApE Biotin GZ-402668 Ibudilast Idebenone Laquinimod Sodium Others It can be also divided ... Global Primary Progressive Multiple Sclerosis Treatment Market 2022 by Company, Regions, Type and Application, Forecast to 2028 ... ApE Biotin GZ-402668 Ibudilast Idebenone Laquinimod Sodium Others Market segment by Application ... Global Primary Progressive Multiple Sclerosis Treatment Market Growth (Status and Outlook) 2024-2030 ... ApE Biotin GZ-402668 Ibudilast Idebenone Laquinimod Sodium Others Segmentation by application Hospital ... Primary Progressive Multiple Sclerosis Treatment Market, Global Outlook and Forecast 2022-2028 ... (%) ApE Biotin GZ-402668 Ibudilast Idebenone Laquinimod Sodium Others Global Primary Progressive ... Autoimmune Disease Therapeutics: Market Research Report This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Million by the following Therapeutic Class: Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics), and Others. The report provides ... Multiple Sclerosis Therapeutics: Market Research Report This report analyzes the worldwide markets for Multiple Sclerosis Therapeutics in US$ Billion. The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual estimates and forecasts are provided for each region for ... Neurodegenerative Drugs: Market Research Report This report analyzes the worldwide markets for Neurodegenerative Drugs in US$ Million by the following disease types: Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Other Neurodegenerative Diseases. The ... Therapy Trends: Multiple Sclerosis An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends. Multiple Sclerosis: On the cusp of a ... Consensus Outlook: Multiple Sclerosis Over the next five years, the global multiple sclerosis (MS) market is set to grow from $14.4 billion in 2012 to $18.3 billion in 2017. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient ... Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules Charting the Future Multiple Sclerosis Market Landscape Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline ... KOL Insight: Multiple Sclerosis Recent launches of oral therapies have brought clinical advantages and clear patient benefits and are set to transform the treatment of Multiple Sclerosis (MS). The question is, which products will rise to become first choice treatments in relapsing forms ... Global Multiple Sclerosis Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 ... (Acordda Therapeutics and Biogen Idec), laquinimod (Active Biotech and Teva Pharmaceuticals ... Crohn’s Disease - Pipeline Insight, 2021 ... CBP-307 TD-1473 JKB-122 Laquinimod PDA-001 IMU-856 ACT ... 2023-2028 Global and Regional Primary Progressive Multiple Sclerosis Treatment Industry Status and Prospects Professional Market Research Report Standard Version ... : ApE Biotin GZ-402668 Ibudilast Idebenone Laquinimod Sodium Others By Applications: Hospital Clinic ... Global Primary Progressive Multiple Sclerosis Treatment Market Research Report 2024(Status and Outlook) ... ) ApE Biotin GZ-402668 Ibudilast Idebenone Laquinimod Sodium Others Market Segmentation (by Application ... Global Multiple Sclerosis Market: Trends & Opportunities (2013-18) ... , Teva hopes its Copaxone successor, laquinimod, may help it preserve some market ... |